Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2014 1
2015 3
2016 3
2017 2
2018 8
2019 3
2020 7
2021 9
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Dexamethasone in Hospitalized Patients with Covid-19.
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. RECOVERY Collaborative Group, et al. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17. N Engl J Med. 2021. PMID: 32678530 Free PMC article. Clinical Trial.
Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between …
Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomi …
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. RECOVERY Collaborative Group, et al. N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8. N Engl J Med. 2020. PMID: 33031652 Free PMC article. Clinical Trial.
Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified subgroups of patients …
Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio …
Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.
Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D; CESAR trial collaboration. Peek GJ, et al. Lancet. 2009 Oct 17;374(9698):1351-63. doi: 10.1016/S0140-6736(09)61069-2. Epub 2009 Sep 15. Lancet. 2009. PMID: 19762075 Clinical Trial.
FINDINGS: 766 patients were screened; 180 were enrolled and randomly allocated to consideration for treatment by ECMO (n=90 patients) or to receive conventional management (n=90). 68 (75%) patients actually received ECMO; 63% (57/90) of patients allocated to consideration for tre …
FINDINGS: 766 patients were screened; 180 were enrolled and randomly allocated to consideration for treatment by ECMO (n=90 patients) or to …
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Wainwright CE, et al. N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17. N Engl J Med. 2015. PMID: 25981758 Free PMC article. Clinical Trial.
In both studies, there were significant improvements in the primary end point in both lumacaftor-ivacaftor dose groups; the difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV1 ranged from 2.6 to 4.0 per …
In both studies, there were significant improvements in the primary end point in both lumacaftor-ivacaftor dose groups; the difference betwe …
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium. Schumacher FR, et al. Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Nat Genet. 2018. PMID: 29892016 Free PMC article.
We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P & …
We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previousl …
Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery.
EuroSurg Collaborative. EuroSurg Collaborative. Br J Surg. 2020 Jan;107(2):e161-e169. doi: 10.1002/bjs.11326. Epub 2019 Oct 9. Br J Surg. 2020. PMID: 31595986 Free article.
After adjustment for baseline differences, the mean time to gastrointestinal recovery did not differ significantly between patients who received NSAIDs and those who did not (46 versus 48 days; hazard ratio 104, 95 per cent c.i. 096 to 112; P = 0360). There were no signifi …
After adjustment for baseline differences, the mean time to gastrointestinal recovery did not differ significantly between patients who rece …
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group. Ramsey BW, et al. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185. N Engl J Med. 2011. PMID: 22047557 Free PMC article. Clinical Trial.
Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001). In addition, through week 48, subjects in the ivacaftor group scored 8.6 points higher than did subjects in the placebo gr …
Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 ( …
Safety of hospital discharge before return of bowel function after elective colorectal surgery.
EuroSurg Collaborative. EuroSurg Collaborative. Br J Surg. 2020 Apr;107(5):552-559. doi: 10.1002/bjs.11422. Epub 2020 Jan 24. Br J Surg. 2020. PMID: 31976560

The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4-7) and 7 (6-8) days respectively (P < 0001). There were no significant differences in rates of readmission between these groups (66 versus 80 per cent;

The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4-7) and 7 (6-8) days r …
25th Annual Computational Neuroscience Meeting: CNS-2016.
Sharpee TO, Destexhe A, Kawato M, Sekulić V, Skinner FK, Wójcik DK, Chintaluri C, Cserpán D, Somogyvári Z, Kim JK, Kilpatrick ZP, Bennett MR, Josić K, Elices I, Arroyo D, Levi R, Rodriguez FB, Varona P, Hwang E, Kim B, Han HB, Kim T, McKenna JT, Brown RE, McCarley RW, Choi JH, Rankin J, Popp PO, Rinzel J, Tabas A, Rupp A, Balaguer-Ballester E, Maturana MI, Grayden DB, Cloherty SL, Kameneva T, Ibbotson MR, Meffin H, Koren V, Lochmann T, Dragoi V, Obermayer K, Psarrou M, Schilstra M, Davey N, Torben-Nielsen B, Steuber V, Ju H, Yu J, Hines ML, Chen L, Yu Y, Kim J, Leahy W, Shlizerman E, Birgiolas J, Gerkin RC, Crook SM, Viriyopase A, Memmesheimer RM, Gielen S, Dabaghian Y, DeVito J, Perotti L, Kim AJ, Fenk LM, Cheng C, Maimon G, Zhao C, Widmer Y, Sprecher S, Senn W, Halnes G, Mäki-Marttunen T, Keller D, Pettersen KH, Andreassen OA, Einevoll GT, Yamada Y, Steyn-Ross ML, Alistair Steyn-Ross D, Mejias JF, Murray JD, Kennedy H, Wang XJ, Kruscha A, Grewe J, Benda J, Lindner B, Badel L, Ohta K, Tsuchimoto Y, Kazama H, Kahng B, Tam ND, Pollonini L, Zouridakis G, Soh J, Kim D, Yoo M, Palmer SE, Culmone V, Bojak I, Ferrario A, Merrison-Hort R, Borisyuk R, Kim CS, Tezuka T, Joo P, Rho YA, Burton SD, Bard Ermentrout G, Jeong J, Urban NN, Marsalek P, Kim HH, Moon SH, Lee DW, Lee SB, Lee JY, Molkov YI, Hamade K, Teka W, Barnett WH, Kim T, Markin S, Rybak IA, Forro C, Dermutz H, Demkó L, Vörös J, Babichev A, Huang H, Verduzco-Flores S, Dos Santos F, Andras P, Metzner C, Schweikard A, Zurowski B, Roach JP, Sander LM, Zochowski MR, Skilling QM, Ognjanovski N, Aton SJ, Zochowski M, Wang SJ, Ouyang G, Guang J, Zhang M, Michael Wong KY, Zhou C, Robinson PA, Sanz-Leon P, Drysdale PM, Fung F, Abeysuriya RG, Rennie CJ, Zhao X, Choe Y, Yang HF, Mi Y, Lin X, Wu S, Liedtke J, Schottdorf M, Wolf F, Yamamura Y, Wickens JR, Rumbell T, Ramsey J, Reyes A, Draguljić D, Hof PR, Luebke J, Weaver CM, He H, Yang X, Ma H, Xu Z, Wang Y, Baek K, Morris LS, Kundu P, Voon V, Agnes EJ, Vogels TP, Podlaski WF, Giese M, Kuravi P, Vogels R, Seeholzer A, Podlaski W, Ranjan R, Vogels T, Torres JJ, Baroni F, Latorre R, Gips B, Lowet E, Roberts MJ, de Weerd P, Jensen O, van der Eerden J, Goodarzinick A, Niry MD, Valizadeh A, Pariz A, Parsi SS, Warburton JM, Marucci L, Tamagnini F, Brown J, Tsaneva-Atanasova K, Kleberg FI, Triesch J, Moezzi B, Iannella N, Schaworonkow N, Plogmacher L, Goldsworthy MR, Hordacre B, McDonnell MD, Ridding MC, Zapotocky M, Smit D, Fouquet C, Trembleau A, Dasgupta S, Nishikawa I, Aihara K, Toyoizumi T, Robb DT, Mellen N, Toporikova N, Tang R, Tang YY, Liang G, Kiser SA, Howard JH Jr, Goncharenko J, Voronenko SO, Ahamed T, Stephens G, Yger P, Lefebvre B, Spampinato GLB, Esposito E, et Olivier Marre MS, Choi H, Song MH, Chung S, Lee DD, Sompolinsky H, Phillips RS, Smith J, Chatzikalymniou AP, Ferguson K, Alex Cayco Gajic N, Clopath C, Angus Silver R, Gleeson P, Marin B, Sadeh S, Quintana A, Cantarelli M, Dura-Bernal S, Lytton WW, Davison A, Li L, Zhang W, Wang D, Song Y, Park S, Choi I, Shin HS, Choi H, Pasupathy A, Shea-Brown E, Huh D, Sejnowski TJ, Vogt SM, Kumar A, Schmidt R, Van Wert S, Schiff SJ, Veale R, Scheutz M, Lee SW, Gallinaro J, Rotter S, Rubchinsky LL, Cheung CC, Ratnadurai-Giridharan S, Shomali SR, Ahmadabadi MN, Shimazaki H, Nader Rasuli S, Zhao X, Rasch MJ, Wilting J, Priesemann V, Levina A, Rudelt L, Lizier JT, Spinney RE, Rubinov M, Wibral M, Bak JH, Pillow J, Zaho Y, Park IM, Kang J, Park HJ, Jang J, Paik SB, Choi W, Lee C, Song M, Lee H, Park Y, Yilmaz E, Baysal V, Ozer M, Saska D, Nowotny T, Chan HK, Diamond A, Herrmann CS, Murray MM, Ionta S, Hutt A, Lefebvre J, Weidel P, Duarte R, Morrison A, Lee JH, Iyer R, Mihalas S, Koch C, Petrovici MA, Leng L, Breitwieser O, Stöckel D, Bytschok I, Martel R, Bill J, Schemmel J, Meier K, Esler TB, Burkitt AN, Kerr RR, Tahayori B, Nolte M, Reimann MW, Muller E, Markram H, Parziale A, Senatore R, Marcelli A, Skiker K, Maouene M, Neymotin SA, Seidenstein A, Lakatos P, Sanger TD, Menzies RJ, McLauchlan C, van Albada SJ, Kedziora DJ, Neymotin S, Kerr CC, Suter BA, Shepherd GMG, Ryu J, Lee SH, Lee J, Lee HJ, Lim D, Wang J, Lee H, Jung N, Anh Quang L, Maeng SE, Lee TH, Lee JW, Park CH, Ahn S, Moon J, Choi YS, Kim J, Jun SB, Lee S, Lee HW, Jo S, Jun E, Yu S, Goetze F, Lai PY, Kim S, Kwag J, Jang HJ, Filipović M, Reig R, Aertsen A, Silberberg G, Bachmann C, Buttler S, Jacobs H, Dillen K, Fink GR, Kukolja J, Kepple D, Giaffar H, Rinberg D, Shea S, Koulakov A, Bahuguna J, Tetzlaff T, Kotaleski JH, Kunze T, Peterson A, Knösche T, Kim M, Kim H, Park JS, Yeon JW, Kim SP, Kang JH, Lee C, Spiegler A, Petkoski S, Palva MJ, Jirsa VK, Saggio ML, Siep SF, Stacey WC, Bernar C, Choung OH, Jeong Y, Lee YI, Kim SH, Jeong M, Lee J, Kwon J, Kralik JD, Jahng J, Hwang DU, Kwon JH, Park SM, Kim S, Kim H, Kim PS, Yoon S, Lim S, Park C, Miller T, Clements K, Ahn S, Ji EH, Issa FA, Baek J, Oba S, Yoshimoto J, Doya K, Ishii S, Mosqueiro TS, Strube-Bloss MF, Smith B, Huerta R, Hadrava M, Hlinka J, Bos H, Helias M, Welzig CM, Harper ZJ, Kim WS, Shin IS, Baek HM, Han SK, Richter R, Vitay J, Beuth F, Hamker FH, Toppin K, Guo Y, Graham BP, Kale PJ, Gollo LL, Stern M, Abbott LF, Fedorov LA, Giese MA, Ardestani MH, Faraji MJ, Preuschoff K, Gerstner W, van Gendt MJ, Briaire JJ, Kalkman RK, Frijns JHM, Lee WH, Frangou S, Fulcher BD, Tran PHP, Fornito A, Gliske SV, Lim E, Holman KA, Fink CG, Kim JS, Mu S, Briggman KL, Sebastian Seung H; the EyeWirers, Wegener D, Bohnenkamp L, Ernst UA, Devor A, Dale AM, Lines GT, Edwards A, Tveito A, Hagen E, Senk J, Diesmann M, Schmidt M, Bakker R, Shen K, Bezgin G, Hilgetag CC, van Albada SJ, Sun H, Sourina O, Huang GB, Klanner F, Denk C, Glomb K, Ponce-Alvarez A, Gilson M, Ritter P, Deco G, Witek MAG, Clarke EF, Hansen M, Wallentin M, Kringelbach ML, Vuust P, Klingbeil G, De Schutter E, Chen W, Zang Y, Hong S, Takashima A, Zamora C, Gallimore AR, Goldschmidt D, Manoonpong P, Karoly PJ, Freestone DR, Soundry D, Kuhlmann L, Paninski L, Cook M, Lee J, Fishman YI, Cohen YE, Roberts JA, Cocchi L, Sweeney Y, Lee S, Jung WS, Kim Y, Jung Y, Song YK, Chavane F, Soman K, Muralidharan V, Srinivasa Chakravarthy V, Shivkumar S, Mandali A, Pragathi Priyadharsini B, Mehta H, Davey CE, Brinkman BAW, Kekona T, Rieke F, Buice M, De Pittà M, Berry H, Brunel N, Breakspear M, Marsat G, Drew J, Chapman PD, Daly KC, Bradle SP, Seo SB, Su J, Kavalali ET, Blackwell J, Shiau L, Buhry L, Basnayake K, Lee SH, Levy BA, Baker CI, Leleu T, Philips RT, Chhabria K. Sharpee TO, et al. BMC Neurosci. 2016 Aug 18;17 Suppl 1(Suppl 1):54. doi: 10.1186/s12868-016-0283-6. BMC Neurosci. 2016. PMID: 27534393 Free PMC article.
Roberts, Leonardo L. Gollo, Michael Breakspear P195 Comparison of three methods to quantify detection and discrimination capacity estimated from neural population recordings Gary Marsat, Jordan Drew, Phillip D. Chapman, Kevin C. Daly, Samual P. Bradley P196 Quantify …
Roberts, Leonardo L. Gollo, Michael Breakspear P195 Comparison of three methods to quantify detection and discrimination capacity est …
FGF-2 promotes osteocyte differentiation through increased E11/podoplanin expression.
Ikpegbu E, Basta L, Clements DN, Fleming R, Vincent TL, Buttle DJ, Pitsillides AA, Staines KA, Farquharson C. Ikpegbu E, et al. J Cell Physiol. 2018 Jul;233(7):5334-5347. doi: 10.1002/jcp.26345. Epub 2018 Jan 23. J Cell Physiol. 2018. PMID: 29215722 Free PMC article.

Exposure of MC3T3 osteoblast-like cells and murine primary osteoblasts to FGF-2 (10 ng/ml) increased E11 mRNA and protein expression (p < 0.05) after 4, 6, and 24 hr. FGF-2 induced changes in E11 expression were also accompanied by significant (p < 0.01) incre

Exposure of MC3T3 osteoblast-like cells and murine primary osteoblasts to FGF-2 (10 ng/ml) increased E11 mRNA and protein expression (p
35 results